Fexofenadine HCl Microspheres – Can it be the First Line Therapy for Allergic Disorders?

Paroma Arefin^1,2 *, Md Shehan Habib¹, Mohammad Mostafa¹, Dipankar Chakraborty¹, Sreebash Chandra Bhattacharjee¹, Md Saidul Arefin³ and Debabrata Karmakar⁴

¹BCSIR Chattogram Laboratories, Bangladesh Council of Scientific and Industrial Research,   Bangladesh

²Institute of Food Science and Technology, Bangladesh Council of Scientific and Industrial Research,   Bangladesh

³Institute of Nutrition and Food Science, University of Dhaka, Dhaka-1000, Bangladesh

⁴Institute of Technology Transfer and Innovation, Bangladesh Council of Scientific and Industrial Research, Bangladesh

Corresponding Author E-mail:paroma.arefin@gmail.com

DOI : http://dx.doi.org/10.13005/bbra/2961

ABSTRACT: Fexofenadine HCl is a second-generation antihistamine which is commonly used for allergic disorders. But it has low bioavailability. Intranasal corticosteroids (INCs) and Immunotherapy and Allergen Specific Immunotherapy (ASIT) are now commonly being suggested for the treatment of allergic disorders. Despite the fact that current treatment alternatives have been in use for decades, patient quality of life has remained static. The treatment options are not much explored for their respective adverse effects. Therefore, they are in desperate need of research. Fexofenadine HCl is available in the form of a suspension, tablet, or capsule. In our current study, we have explored whether microspheres can be the perfect dosage form of Fexofenadine HCl to treat allergic disorders considering the pharmacokinetics of the drug, available dosage forms options and the probable side effects of the current therapies.

KEYWORDS: Allergen Specific Immunotherapy (ASIT);  Allergic disorder; Fexofenadine HCl; Half-life, Intranasal corticosteroids (INCs); Microsphere

[ HTML Full Text]